WO1998045477A3 - Methods for assessing cardiovascular status and compositions for use thereof - Google Patents

Methods for assessing cardiovascular status and compositions for use thereof Download PDF

Info

Publication number
WO1998045477A3
WO1998045477A3 PCT/IB1998/000475 IB9800475W WO9845477A3 WO 1998045477 A3 WO1998045477 A3 WO 1998045477A3 IB 9800475 W IB9800475 W IB 9800475W WO 9845477 A3 WO9845477 A3 WO 9845477A3
Authority
WO
WIPO (PCT)
Prior art keywords
cardiovascular status
methods
compositions
agt
ace
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1998/000475
Other languages
French (fr)
Other versions
WO1998045477A2 (en
Inventor
Leif Torbjoern Norberg
Maria Kristina Andersson
Per Harry Rutger Lindstroem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eurona Medical AB
Original Assignee
Eurona Medical AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP54253098A priority Critical patent/JP2001519660A/en
Priority to IL13209998A priority patent/IL132099A0/en
Priority to DE69835509T priority patent/DE69835509T2/en
Priority to CA002285671A priority patent/CA2285671A1/en
Priority to AU66329/98A priority patent/AU741750B2/en
Priority to EP98908252A priority patent/EP0972075B1/en
Application filed by Eurona Medical AB filed Critical Eurona Medical AB
Priority to NZ337878A priority patent/NZ337878A/en
Publication of WO1998045477A2 publication Critical patent/WO1998045477A2/en
Publication of WO1998045477A3 publication Critical patent/WO1998045477A3/en
Anticipated expiration legal-status Critical
Priority to CY20061101603T priority patent/CY1106158T1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

Abstract

The present invention provides methods for assessing cardiovascular status in an individual, which comprise determining the sequence at one or more polymorphic positions within the human genes encoding angiotensin converting enzyme (ACE), angiotensinogen (AGT), and/or type 1 angiotensin II receptor (AT1). The invention also provides isolated nucleic acids endoding ACE, AGT, and AT1 polymorphisms, nucleic acid probes that hybridize to polymorphic positions, kits for the prediction of cardiovascular status, and nucleic acid and peptide targets for use in identifying candidate cardiovascular drugs.
PCT/IB1998/000475 1997-04-04 1998-04-01 Methods for assessing cardiovascular status and compositions for use thereof Ceased WO1998045477A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IL13209998A IL132099A0 (en) 1997-04-04 1998-04-01 Methods for assessing cardiovascular status and compositions for use therein
DE69835509T DE69835509T2 (en) 1997-04-04 1998-04-01 METHOD FOR DETERMINING THE CARDIOVASCULAR STATUS AND COMPOSITIONS FOR ITS USE
CA002285671A CA2285671A1 (en) 1997-04-04 1998-04-01 Methods for assessing cardiovascular status and compositions for use thereof
AU66329/98A AU741750B2 (en) 1997-04-04 1998-04-01 Methods for assessing cardiovascular status and compositions for use thereof
EP98908252A EP0972075B1 (en) 1997-04-04 1998-04-01 Methods for assessing cardiovascular status and compositions for use thereof
JP54253098A JP2001519660A (en) 1997-04-04 1998-04-01 Methods for assessing cardiovascular conditions and compositions for using the same
NZ337878A NZ337878A (en) 1997-04-04 1998-04-01 Methods for assessing cardiovascular status using polymorphisms in the ACE, AGT or AT1 genes, and compositions for use thereof
CY20061101603T CY1106158T1 (en) 1997-04-04 2006-11-08 METHODS FOR ASSESSING CARDIAC STATUS AND COMPOSITIONS FOR THEIR USE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4293097P 1997-04-04 1997-04-04
US60/042,930 1997-04-04

Publications (2)

Publication Number Publication Date
WO1998045477A2 WO1998045477A2 (en) 1998-10-15
WO1998045477A3 true WO1998045477A3 (en) 1999-01-28

Family

ID=21924511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/000475 Ceased WO1998045477A2 (en) 1997-04-04 1998-04-01 Methods for assessing cardiovascular status and compositions for use thereof

Country Status (13)

Country Link
US (1) US6197505B1 (en)
EP (1) EP0972075B1 (en)
JP (1) JP2001519660A (en)
AT (1) ATE335844T1 (en)
AU (1) AU741750B2 (en)
CA (1) CA2285671A1 (en)
CY (1) CY1106158T1 (en)
DE (1) DE69835509T2 (en)
DK (1) DK0972075T3 (en)
ES (1) ES2270510T3 (en)
IL (1) IL132099A0 (en)
NZ (1) NZ337878A (en)
WO (1) WO1998045477A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197505B1 (en) 1997-04-04 2001-03-06 Pyrosequencing Ab Methods for assessing cardiovascular status and compositions for use thereof
ES2238770T5 (en) * 1997-10-17 2012-01-17 Ark Therapeutics Limited USE OF INHIBITORS OF THE RENIN-ANGIOTENSIN SYSTEM FOR THE TREATMENT OF HYPOXIA OR DECREASE OF METABOLIC FUNCTION.
JP2002527079A (en) * 1998-10-14 2002-08-27 パイロシーケンシング・アーベー Genes for assessing cardiovascular status and compositions for their use
US6280994B1 (en) * 1998-11-25 2001-08-28 Zymogenetics, Inc. Zace 1: a human metalloenzyme
WO2000056922A2 (en) * 1999-03-23 2000-09-28 Gemini Genomics Ab Genetic polymorphism and polymorphic pattern for assessing disease status, and compositions for use thereof
GB9914440D0 (en) * 1999-06-22 1999-08-18 Zeneca Ltd Chemical compounds
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
US7141370B2 (en) * 2001-07-03 2006-11-28 The Board Of Trustees Of The Leland Stanford Junior University Bioluminescence regenerative cycle (BRC) for nucleic acid quantification
EP1394267A1 (en) * 2002-08-19 2004-03-03 Bayer HealthCare AG Single nucleotide polymorphisms predictive for cardiovascular disease, adverse drug reactions, and drug efficacy
US20040197793A1 (en) * 2002-08-30 2004-10-07 Arjang Hassibi Methods and apparatus for biomolecule detection, identification, quantification and/or sequencing
WO2005083127A2 (en) * 2004-02-27 2005-09-09 Applera Corporation Genetic polymorphisms associated with stroke, methods of detection and uses thereof
CN100540678C (en) * 2004-04-15 2009-09-16 香港中文大学 Method for predicting diabetic nephropathy risk by applying genetic marker and chip
WO2006123885A1 (en) * 2005-05-18 2006-11-23 Samsung Electronics Co., Ltd. Methods and compositions for diagnosing cardiovascular disease
US9012143B2 (en) * 2007-04-30 2015-04-21 The Ohio State University Research Foundation Polymorphisms in genes affecting ace-related disorders and uses thereof
WO2010096680A2 (en) 2009-02-20 2010-08-26 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Protein structural biomarkers to guide targeted chemotherapies
US9938576B1 (en) 2012-09-21 2018-04-10 Ohio State Innovation Foundation Materials and methods for determining metabolizer status in humans

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000360A1 (en) * 1991-06-27 1993-01-07 Institut National De La Sante Et De La Recherche Medicale Methods and means for studying genetic polymorphism in the angiotensin converting enzyme
WO1994008048A1 (en) * 1992-09-30 1994-04-14 University Of Utah Research Foundation Angiotensinogen gene variants and predisposition to hypertension
WO1996005324A1 (en) * 1994-08-09 1996-02-22 Institut National De La Sante Et De La Recherche Medicale Method for in vitro detection of a predisposition to myocardial infarction and diagnostic kit

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0234095A3 (en) 1985-10-24 1988-06-15 Biotechnology Research Partners, Ltd. Blood tests diagnostic for hypertension
AU1728088A (en) 1987-04-30 1988-12-02 Biotechnology Research Partners Limited Hypertension-related blood tests useful as genetic markers
US5243652A (en) * 1992-09-30 1993-09-07 Gte Laboratories Incorporated Location-sensitive remote database access control
US5800990A (en) 1995-12-06 1998-09-01 Regents Of The University Of Colorado Angiotensin-converting enzyme genetic variant screens
US6197505B1 (en) 1997-04-04 2001-03-06 Pyrosequencing Ab Methods for assessing cardiovascular status and compositions for use thereof
EP1044268A1 (en) 1997-12-30 2000-10-18 Max-Delbrück-Centrum Für Molekulare Medizin Novel sequence variants of the human beta2-adrenergic receptor gene and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000360A1 (en) * 1991-06-27 1993-01-07 Institut National De La Sante Et De La Recherche Medicale Methods and means for studying genetic polymorphism in the angiotensin converting enzyme
WO1994008048A1 (en) * 1992-09-30 1994-04-14 University Of Utah Research Foundation Angiotensinogen gene variants and predisposition to hypertension
WO1996005324A1 (en) * 1994-08-09 1996-02-22 Institut National De La Sante Et De La Recherche Medicale Method for in vitro detection of a predisposition to myocardial infarction and diagnostic kit

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TIRET L ET AL: "SYNERGISTIC EFFECT OF ANGIOTENSIN-CONVERTING ENZYME AND ANGIOTENSIN-II TYPE 1 RECEPTOR GENE POLYMORPHISMS ON RISK OF MYOCARDIAL INFARCTION", LANCET THE, vol. 344, 1 October 1994 (1994-10-01), pages 910 - 913, XP000619739 *

Also Published As

Publication number Publication date
IL132099A0 (en) 2001-03-19
NZ337878A (en) 2001-09-28
CY1106158T1 (en) 2011-06-08
DK0972075T3 (en) 2006-12-11
US6197505B1 (en) 2001-03-06
DE69835509T2 (en) 2007-04-05
EP0972075B1 (en) 2006-08-09
AU741750B2 (en) 2001-12-06
ATE335844T1 (en) 2006-09-15
AU6632998A (en) 1998-10-30
CA2285671A1 (en) 1998-10-15
EP0972075A2 (en) 2000-01-19
WO1998045477A2 (en) 1998-10-15
ES2270510T3 (en) 2007-04-01
JP2001519660A (en) 2001-10-23
DE69835509D1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
IL132099A0 (en) Methods for assessing cardiovascular status and compositions for use therein
WO2001013086A3 (en) Detection of nucleic acids
DK0805876T3 (en) Nucleic acid amplification oligonucleotides and probes for Lyme disease-associated Borrelia
EP2474632A3 (en) Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
WO2002018638A3 (en) Detection of cyp2d6 polymorphisms
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
DE60030145D1 (en) DETECTION PROCEDURE FOR SHORT SEQUENCE VARIANTS
WO2000022166A3 (en) Genes for assessing cardiovascular status and compositions for use thereof
WO2001000803A3 (en) Apolipoprotein a-iv-related protein: polypeptide, polynucleotide sequences and biallelic markers thereof
WO2004044163A3 (en) Methods for identifying risk of melanoma and treatments thereof
CA2303414A1 (en) Non-competitive co-amplification methods
WO2000004192A8 (en) Methods for detecting and mapping genes, mutations and variant polynucleotide sequences
WO1996040040A3 (en) Thrombin receptor homolog
WO2003072828A3 (en) Fcgammariib polymorphisms detection in system lupus erythematosus
CA2294476A1 (en) Semaphorin receptors
WO2000009693A3 (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
WO2007027867A3 (en) Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2005046459A3 (en) Primers, methods and kits for detecting killer-cell immunoglobulin-like receptor alleles
WO1999057315A3 (en) Mmp-9 gene polymorphisms
AU3775099A (en) Methods, kits and compositions for detecting and quantitating target sequences
WO1996039511A3 (en) A c5a-like seven transmembrane receptor
ES2308852T3 (en) GENOMIC AND COMPLETE SEQUENCES OF CDNA OF HUMAN APM1 SPECIFIC FOR ADIPOCITOS AND BIALELIC MARKERS OF THE SAME.
AU2002335491A1 (en) Test system for determining gene toxicities
WO2001040522A3 (en) Short shared nucleotide sequences
DE60025336D1 (en) METHOD AND KIT FOR EARLY DETECTION OF CANCER

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 132099

Country of ref document: IL

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CY CZ DE DK EE ES FI GB GE GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CY CZ DE DK EE ES FI GB GE GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 337878

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2285671

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2285671

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/009044

Country of ref document: MX

Ref document number: 66329/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 1998 542530

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998908252

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998908252

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 66329/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998908252

Country of ref document: EP